The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
If we are going to be patronising then I would advise you to use your eyes and read the RNS, prior RNS's and Anne's interview Soup.
These types of studies, given how small the company is, will take 6 months or so. I don't expect to see anything until at least mid Q3
Good to see things are progressing. But given the work they are carrying out, I don't see any substantial news landing over the next few months. Ox deal isn't substantial
that definitely won't happen
Its honestly astounding how many PI's don't understand regulatory approvals yet seem to think they are experts. The fact of the matter is, CE mark is DONE, the rest is a formality. The more interesting part of the RNS is the European aspect which no one seems to be talking about!
regurgitating old news still..
Oh dear. Just read that RNS. Surprised group hasn't replied since he said Jo is the secret weapon.
Anyway, psychologically, I have lost all of my money, the way Im thinking of it is if I break even, Im in profit lol
Its genuinely hilarious how people act on this board. We have steadily ticked pretty much every single box and people are crying over the MHRA being late to respond to US (not the other way round). Its a formality ffs. The same people that wet themselves now will be coming with rocket emojis when the RNS lands. Its pathetic.
Its coming very soon and orders will follow. Just be patient.
I think many of the antivirals they are looking at are from companies that are not British, I think someone posted a list of all of them a couple of weeks ago. I also beleive the preference is a home based antiviral, rather than hospitalised patients
Probably not. However, I have it on good authority that the government is indeed heavily stockpiling on antivirals at the moment in molecules that haven't read out PII results let alone PIII. I think this bodes well for us.
They want antivirals in place for Autumn and are buying at risk of trials failing.